GCP
PDSB icon

GSA Capital Partners’s PDS Biotechnology PDSB Stock Holding History

GSA Capital Partners’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,358
Closed -$41K – 1939
2024
Q1 		$41K Buy
+10,358
New +$53.4K ﹤0.01% 1539
2022
Q2 		– Sell
-14,321
Closed -$89K – 1708
2022
Q1 		$89K Buy
+14,321
New +$89K 0.01% 1306

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's PDSB Position: Q2 2024 in Review

GSA Capital Partners sold out of PDS Biotechnology (PDSB) in Q2 2024, closing a stake of 10,358 shares — an estimated $41K sold.

GSA Capital Partners first reported a position in PDSB in Q1 2022 and held it in 2 quarters. The position peaked at $89K in Q1 2022. 77 funds tracked by Wall St. Rank hold PDSB as of Q2 2024.

  • GSA Capital Partners reported no remaining PDS Biotechnology position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 10,358 PDS Biotechnology shares in Q2 2024, an estimated $41K.
  • GSA Capital Partners first reported a position in PDS Biotechnology in Q1 2022 and held it in 2 quarters.
  • GSA Capital Partners's PDS Biotechnology position peaked at $89K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.